| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02018367 | Barrett's Esophagus | Drug: Proflavine, high resolution imaging | Anandasabapathy, Sharmila, M.D.|William Marsh Rice University | Phase 1 | 2012-09-01 | 2017-01-25 |
| NCT02029937 | Suspected or Known Squamous Cell Neoplasia|Prior History of Squamous Cell Dysplasia and /or Neoplasia | Drug: Proflavine, high resolution imaging | Anandasabapathy, Sharmila, M.D.|William Marsh Rice University | Phase 2 | 2014-01-01 | 2016-07-11 |
| NCT01384227 | Barrett's Esophagus | Drug: Proflavine Hemisulfate | Anandasabapathy, Sharmila, M.D.|Icahn School of Medicine at Mount Sinai | Early Phase 1 | 2009-02-01 | 2016-01-08 |
| NCT01384240 | Colon Polyps|Colonic Dysplasia|Anal Dysplasia | Drug: Proflavine Hemisulfate | Anandasabapathy, Sharmila, M.D. | Early Phase 1 | 2010-04-01 | 2016-01-08 |
| NCT01384708 | Squamous Cell Cancer | Drug: proflavine | Anandasabapathy, Sharmila, M.D.|William Marsh Rice University | Early Phase 1 | 2010-08-01 | 2016-01-07 |
| NCT01384695 | GERD|Barrett's Esophagus | Drug: Fluorescein|Drug: Proflavine hemisulfate | Anandasabapathy, Sharmila, M.D. | Early Phase 1 | 2009-06-01 | 2016-01-08 |
| NCT01456143 | Squamous Cell Carcinoma|Neoplasia|Head and Neck Cancer | Device: High Resolution Microendoscopy (HRME)|Other: Proflavine hemisulfate | Sharmila Anandasabapathy, MD|William Marsh Rice University|Anandasabapathy, Sharmila, M.D. | 2011-12-01 | 2016-05-06 |
| NCT01384864 | Barrett's Esophagus|Intraepithelial Neoplasia | Drug: proflavine | Anandasabapathy, Sharmila, M.D.|William Marsh Rice University | Early Phase 1 | 2011-08-01 | 2016-01-07 |
| NCT01269190 | Head and Neck Cancer | Drug: Proflavine|Procedure: Imaging|Device: Widefield Multispectral Imaging Devices|Device: High-Resolution Microendoscope (HRME) | M.D. Anderson Cancer Center|National Institutes of Health (NIH) | | 2010-12-01 | 2016-08-10 |
| NCT02714439 | Malignant Neoplasms of Female Genital Organs | Drug: Proflavine|Procedure: High-Resolution Microendoscopy (HRME) | M.D. Anderson Cancer Center|University of Texas | Early Phase 1 | 2017-02-01 | 2016-11-09 |
| NCT02206048 | Cervix Carcinoma | Drug: Proflavine|Procedure: High-Resolution Microendoscopy (HRME) Imaging | M.D. Anderson Cancer Center | | 2015-10-01 | 2016-12-01 |
| NCT02095847 | Uterine Cancer | Procedure: High-Resolution Microendoscopy Imaging|Drug: Proflavine | M.D. Anderson Cancer Center|Ovarian Spore | Phase 2 | | 2015-04-07 |
| NCT02790853 | Cancer of Head and Neck|Oral Potentially Malignant Disorders | Procedure: White Light (WL) Clinical Examination|Device: PS2.1/PS3 Imaging|Other: Proflavine Hemisulfate|Device: High-Resolution Optical System (HRME)|Procedure: Brush Biopsy|Procedure: Tissue Biopsy | M.D. Anderson Cancer Center|National Institutes of Health (NIH)|William Marsh Rice University|National Cancer Institute (NCI) | 2016-05-01 | 2016-11-30 |
| NCT02207959 | Gastric Cancer | Drug: Proflavine Hemisulphate salt|Procedure: White-light examination|Procedure: Imaging with High Resolution Microendoscope | Susana Gonzalez|William Marsh Rice University|Icahn School of Medicine at Mount Sinai | Phase 1 | 2015-01-01 | 2015-01-12 |
| NCT02335372 | Cervical Cancer | Procedure: Wide-Field White Light Imaging|Drug: Acetic Acid|Drug: Proflavine Solution|Procedure: Wide-Field Fluorescence Imaging | M.D. Anderson Cancer Center | | 2013-06-01 | 2017-03-08 |
| NCT02420665 | Cervical Cancer | Drug: Proflavine|Device: HRME Imaging|Behavioral: Phone Call|Procedure: Colposcopy|Drug: Acetic Acid | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|National Institutes of Health (NIH) | 2015-09-01 | 2016-08-16 |
| NCT02494310 | Neoplasia of the Uterine Cervix|Cancer Prevention|Cervical Intraepithelial Neoplasia | Device: High-Resolution Microendoscopy Imaging | Barretos Cancer Hospital|William Marsh Rice University|M.D. Anderson Cancer Center|National Institutes of Health (NIH) | 2015-09-01 | 2017-02-01 |
